New drug hopes to strengthen muscles in rare genetic disorder

NCT ID NCT07560020

First seen May 05, 2026 · Last updated May 05, 2026

Summary

This study tests a medicine called surlorian in 28 adults with a rare genetic muscle disease (RYR1-related myopathy). The goal is to see if it improves muscle strength and is safe. Participants will be randomly assigned to receive surlorian or a placebo, and neither they nor the doctors will know which they get.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT RYR1-RELATED MYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AP-HM- Hôpital de La Timone

    Marseille, Bouches-du-Rhône, 13385, France

  • Charité - Campus Berlin Buch

    Berlin, State of Berlin, 13125, Germany

  • Hospital Universitario Vall d'Hebron - PPDS

    Barcelona, Barcelona, 8035, Spain

  • Hospital Universitario de Donostia

    San Sebastián, Guipúzcoa, 20014, Spain

  • Institut de Myologie - Hôpital de La Pitié-Salpétrière

    Paris, 73013, France

  • Radboud Universitair Medisch Centrum

    Nijmegen, Gelderland, 6500 HB, Netherlands

  • The Robert Jones and Agnes Hunt Orthopaedic Hospital

    Oswestry, Shropshire, SY10 7AG, United Kingdom

  • University College Hospital - PPDS

    London, WC1N 3BG, United Kingdom

  • Universitätsklinikum Ulm

    Ulm, Baden-Wurttemberg, 89081, Germany

Conditions

Explore the condition pages connected to this study.